The Munich-based company GNA Biosolutions, which was already supported by SANEMUS AG in the Series C financing round in August 2019, has developed a particularly rapid Covid-19 test, which is to be launched on the market in June at the latest.

The GNA Covid-19 system will consist of a portable testing device which can detect coronavirus for up to 8 samples at a time, in 15 minutes or less.

The tests and system will be provided to first responders and laboratories and can also be used in drive through testing sites. Anticipated availability for the first systems and tests is 8-12 weeks.

You can find the complete article of the Süddeutsche Zeitung here

More information about GNA Biosolutions can be found here

The theme for 11th October 2019 is Corporate Governance – Who controls the supervisory board?

Ideas and inspiration will be provided by Daniela Bergdolt, Vice President of Deutsche Schutzvereinigung für Wertpapierbesitz e.V., Düsseldorf, and Prälat Dr. Lorenz Wolf, Chairman of the Chairman’s Conference of the Boards (Supervisory Board) of ARD, Munich.

In addition, Dr. Joachim Faber, Chairman of the Supervisory Board of Deutsche Börse AG, Frankfurt am Main, will bid farewell to the participants with a dinner speech.

Detailed information on the event can be found at

The SANEMUS team has successfully supported the German Diagnostics Start-up GNA Biosolutions GmbH in its series C financing round. In the end 13.5 M$ were raised from well-known investors. Further information can be found in the press release 



SANEMUS supports a biotech start-up in fundraising. The start-up focusses on diabetic complications and is currently developing the first causal, anti-infalmmatory treatment of diabetic nephropathy. 

If you are interested in an investment, please contact us. 


Dr. Michael Thiel publishes Part III of the three-part series on venture capital in the German life-science-industry for the journal pharmind. The focus is on the consideration of institutional venture-capital-funds, which are the largest and most important investors for life science start-ups. An overview of selected European and German life science venture-capital-funds should clarify the backlog for venture capital in Germany. Finally, the investment strategies of the funds and investment opportunities for interested investors are presented.

You can find the whole article here  (German-language link)

Dr. Michael Thiel published the second part of the three-part series on venture capital in the German life-science-industry. The article focuses on the role of life-science-corporate-venture-fonds for the innovation strategy of pharma and biotechnology companies. Moreover the motivation of corporate-venture-fonds for their investments and the differences in contrast to institutional venture-capital-fonds are discussed.

You can find the whole article here → (German-language link)

SANEMUS supports a German biotech start-up in searching venture capital. With its innovative, patented compound, the company offers a completely new therapeutic approach for the treatment of HIV patients who are resistant to therapy. Initial talks with institutional VCs have already been started. If you are interested in participating, please contact us. 

SANEMUS supports a telemedicine start-up in fundraising. The start-up has developed a telemedicine system for the adjustment of medication of Parkinson’s Disease patients at home. After a successful test phase in inpatient and outpatient care, the market launch of the system in Germany is scheduled for autumn 2018. First talks with potential investors are being held. If you are interested in participating, please contact us.

SANEMUS has a new board of directors. Chairman is Dr. Theo Trucksaess assisted by Dr. Dr. Michael Dahm and Bernd Seibel. 

Dr. Theo Trucksaess is European Partner of Shentou Investment Co. Ltd. Dr. Dr. Michael Dahm is CMO of ORYX GmbH & Co. KG. Bernd Seibel, former General Partner at TVM, is investing as Business Angel in different Life Science companies.

The SANEMUS team welcomes the new members of the board of directors and is looking forward to the cooperation!

In the cover story of the latest issue of Life Sciences Platform, “Biotechnology 2017”, Dr. Thiel gives an overview of the development of the life science industry in the current year.

Many doubts were raised trough electioneering in the US in 2016,  but meanwhile the optimism in the growth of the life science market is back. Amongst other things, the end of the discussion about a regulation of drug pricing in the US and the abandon of plans for a health care and corporate tax reform, resulted in positive impulses at the stock exchange.

You can read the whole article here→  (German-language link)